

REMARKS

Pursuant to 37 C.F.R. § 1.98 copies of the U.S. patent documents (patents, application publications, and applications) are not being submitted herewith. Of course, should any of the documents not be readily available to the Examiner, the Examiner is requested to contact the undersigned and additional copies will be submitted.

Applicants note that Copyrighted material submitted with this Information Disclosure Statement may be delivered to the Government under license from the Copyright Clearance Center, Inc., or other rights holders – no further reproduction of such works is permitted.

Inclusion of any reference is not intended to constitute an admission that the reference is "prior art" unless it is specifically designated as such.

This Information Disclosure Statement is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore no fee is due. However please charge any fees should they be required to Novo Nordisk Inc. Deposit Account No. 14-1447.

Applicants respectfully request that any references or other information listed above be made of record in this patent application. The Examiner is invited to call the undersigned if there are any questions concerning this submission or application.

Respectfully submitted,

Date: November 4, 2010

/Marc A. Began, Reg. No. 48,829/
Marc A. Began, Reg. No. 48,829
Novo Nordisk Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE